louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06165718: Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.
Official title: A Multicenter, Observational Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pulmonary Artery Sarcoma
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital of Guangzhou Medical University
name: Beijing Chao Yang Hospital
name: Shanghai Pulmonary Hospital, Shanghai, China
name: Sir Run Run Shaw Hospital
name: Beijing Anzhen Hospital
First posted: 2023-12-11
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pulmonary artery sarcoma patients expected to complete follow-up

Brief summary: This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Detailed description: This is an observational study covering mainland China, and patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Eligibility criteria: Inclusion Criteria:

* Computed tomography pulmonary angiography indicated that there were intraluminal defects
* Malignant histopathology was sarcoma
* Informed consent form was signed

Exclusion Criteria:

* Life expectancy was less than 3 months due to diseases other than pulmonary artery sarcoma
* Expected inability to complete follow-up

Primary outcomes:
measure: Progression-free survival
timeFrame: 36 months
Secondary outcomes:
measure: Overall survival
timeFrame: 36 months
measure: Postoperative survival
timeFrame: 36 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: China-Japan Friendship Hospital
state: Beijing
Study officials:
affiliation: China-Japan Friendship Hospital
name: Wanmu Xie
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00037518: A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer
Official title: An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hyperparathyroidism
Parathyroid Neoplasms
Keywords: Severe primary hyperparathyroidism
Parathyroid carcinoma
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2002-05-20
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.


Eligibility criteria: * Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; \* Abnormally elevated calcium levels above 12.5 mg/dL; \* Not be pregnant or nursing; \* Not have had any type of cancer other than parathyroid carcinoma within the last 5 years.

Primary outcomes:
measure: Changes in serum calcium and PTH
Secondary outcomes:
measure: Safety and tolerability of cinacalcet
Other outcomes:
Locations:
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References:
citation: Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007 Oct;92(10):3803-8. doi: 10.1210/jc.2007-0585. Epub 2007 Jul 31.
citation: Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009 Aug;94(8):2766-72. doi: 10.1210/jc.2008-2640. Epub 2009 May 26.
citation: Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab. 2011 Jan;96(1):E9-18. doi: 10.1210/jc.2010-1221. Epub 2010 Oct 13.
Clinical trial NCT01403818: A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration
Official title: Pharmacokinetic Study of ASP1941 -A Pharmacokinetic Study to Assess Drug-Drug Interaction Between ASP1941 and Mitiglinide Calcium Hydrate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Pharmacokinetics of ASP1941
Pharmacokinetics of Mitiglinide
Keywords: ASP1941
ipragliflozin
Mitiglinide calcium hydrate
Drug-Drug interaction
Pharmacokinetics
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2011-07-27
Enrollment: 60
Sex: MALE
Minimum age (years): 20
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: This study is to assess the pharmacokinetic interaction between ASP1941 and Mitiglinide calcium hydrate in healthy volunteers.

Detailed description: This will be a randomized, open label, four group, two-way crossover design study to assess the effect of drug interaction between ASP1941 and Mitiglinide calcium hydrate on the pharmacokinetics of them after separate and concomitant administration to healthy non-elderly adult male subjects.

Eligibility criteria: Inclusion Criteria:

* Healthy as judged by the investigator/subinvestigator based on the results of physical examinations and laboratory tests
* Body weight ; ≥50.0 kg, \<80.0 kg
* Body Mass Index ; ≥17.6, \<26.4 kg/m2
* Written informed consent has been obtained

Exclusion Criteria:

* Received any investigational drugs within 120 days before the screening assessment
* Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or d components within 14 days before the screening assessment
* Received medication within 7 days before hospital admission
* A deviation from the assessment criteria of physical examinations or laboratory tests at screening or upon admission
* History of drug allergies
* With renal, hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases
* Previous treatment with ASP1941

Primary outcomes:
measure: Pharmacokinetics of ASP1941 and Mitiglinide calcium hydrate assessed by its plasma concentration change
timeFrame: For up to 72 hours after each administration
Secondary outcomes:
measure: Safety assessed by incidence of adverse event, vital signs, 12-lead ECG and laboratory tests
timeFrame: For up to 10 days
measure: Pharmacokinetics of the metabolites of ASP1941 assessed by its plasma concentration change
timeFrame: For 72 hours after ASP1941 administration
Other outcomes:
Locations:
city: Kantou
country: Japan
Study officials:
affiliation: Astellas Pharma Inc
name: Use Central Contact
role: STUDY_CHAIR
References:
Clinical trial NCT05881018: Investigating the Effects of Diet and Physical Activity on Esport Performance
Official title: Investigating the Effects of Diet and Physical Activity on Esport Performance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sports Physical Therapy
Dietary Habits
Diet, Healthy
Lead sponsor: Beneo-Institute
Sponsor class: INDUSTRY
Collaborators: name: German Sport University, Cologne
First posted: 2023-05-30
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: A randomized, counterbalanced intervention study in esport players.

Detailed description: The study will test whether i) the consumption of two different carbohydrate drinks and ii) the performance of regular high-intensity interval training will impact esport performance and metabolic profile.

Eligibility criteria: Inclusion Criteria:

* Informed consent obtained
* Male or female aged 18-45 years
* Healthy
* Participants have to be part of an esport association and/or regularly participate in tournaments

Exclusion Criteria:

* diabetes mellitus type 1 or 2 (T1DM or T2DM)
* medication which impacts glucose metabolism or visual perception
* health issues like cardiovascular diseases, severe orthopaedic conditions or neurological impairments
* food allergies or intolerances, e.g. fructose malabsorption

Primary outcomes:
measure: Change in esport performance (test battery)
timeFrame: 4 weeks
Secondary outcomes:
measure: Glucose response (continuous glucose monitor): 3h iAUC
timeFrame: 4 weeks
measure: Glycaemic variability (continuous glucose monitor): 24h MAGE
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: German Sports University Cologne
Study officials:
References:
Clinical trial NCT01892618: Pneumococcal Vaccine in Untreated CLL Patients
Official title: A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Lymphocytic Leukemia
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
First posted: 2013-07-04
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine whether patients with chronic lymphocytic leukaemia (CLL) will benefit from vaccination with a 13-valent conjugated pneumococcal vaccine, Prevenar13, compared with a conventional 23-valent capsular polysaccharide vaccine in terms of immune response.


Eligibility criteria: Inclusion Criteria:

* Untreated CLL patients all Rai stages (0 to IV), as early as possible after diagnosis, always before any therapy with monoclonal antibodies and/or chemotherapy

Exclusion Criteria:

* Immunosuppressive therapy planned to start within 1 month
* Other malignancies
* Corticosteroids or other immunosuppressive drugs
* Previous allergic reaction to any vaccination in the past
* Neutropenia (PMNs \< 500 cells/mm3)

Primary outcomes:
measure: Immune response to Pneumovax compared to immune response to Prevenar
timeFrame: 1 month post vaccination
Secondary outcomes:
measure: Serotype-specific immunoglobulin G (IgG) antibody levels
timeFrame: 1 and 6 months post vaccination
measure: Levels of opsonophagocytic antibodies (OPA)
timeFrame: 6 months post vaccination
measure: Serotype-specific IgG antibody levels by ELISA, geometric mean concentrations (GMCs)between arms
timeFrame: 1 and 6 months post vaccination
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Karolinska University Hospital
Study officials:
affiliation: Karolinska University Hospital, SE-141 86 Stockholm, Sweden
name: Eva Kimby, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00480818: Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects
Official title: An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Young and Elderly Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer Disease
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2007-05-31
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy young adult and elderly subjects.To assess the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy young adult and elderly subjects.


Eligibility criteria: Inclusion criteria :

* Men or women of nonchildbearing potential aged 18 to 45 years
* Elderly men or women aged 65 years and above as of study day 1.
* Body mass index in the range of 18 to 30 kg/m2 and body weight ≥50 kg. Body weight for elderly subjects must be ≥45 kg.

Exclusion criteria:

* Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
* Any clinically important deviation from normal limits in physical examination, vital signs, digital 12-lead ECGs, or clinical laboratory test results.
* Tobacco use or the consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or soda) or alcoholic beverages within 48 hours before study day 1, or grapefruit or grapefruit-containing products 72 hours before study day 1, and until the end of the inpatient confinement period.
* Elderly men or women aged 65 years and above as of study day 1.
* Body mass index in the range of 18 to 30 kg/m2 and body weight ≥50 kg. Body weight for elderly subjects must be ≥45 kg.

Primary outcomes:
measure: Safety and tolerability
Secondary outcomes:
measure: Pharmacokinetics and pharmacodynamics
Other outcomes:
Locations:
city: Rennes
country: France
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01276418: ENT FiberLase CO2 Study
Official title: ENT FiberLase CO2 Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Laryngeal Diseases
Pharyngeal Diseases
Lead sponsor: Lumenis Be Ltd.
Sponsor class: INDUSTRY
First posted: 2011-01-13
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is intended to collect data regarding treatment with a new flexible fiber used to transmit laser emitted from a Carbon dioxide (CO2) laser to the transoral region. This study will include a single treatment that is performed transorally (through the mouth) for oral or laryngeal indications in the field of Ear, Nose and Throate (ENT).


Eligibility criteria: Inclusion Criteria:

1. General good health allowing patient to undergo general anaesthesia or heavy sedation according to the specific procedure.
2. Adult
3. Able and willing to comply with all visit, treatment and evaluation schedule and requirements
4. Able to understand and provide written Informed Consent
5. Disease which requires tissue ablation for treatment

Exclusion Criteria:

1. Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to each treatment (as per the patient's physician discretion);
2. Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Physician would interfere with the anesthesia, treatment, or healing process
3. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse;
4. Any condition which, in the Physician's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research

Primary outcomes:
measure: Ability to complete procedure with the study device
timeFrame: Immediate - during intervention
measure: Complications (bleeding, perforation, damage to non target tissue)
timeFrame: During intervention and up to 6 weeks following the procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Yvoir
country: Belgium
facility: University Hospital of Mont-Godinne
city: Cesena
country: Italy
facility: Bufalini Hospital
Study officials:
References:
Clinical trial NCT01723618: Pharmacokinetics of CRD007 in Patients With Abdominal Aorta Aneurisms.
Official title: An Open-label, Randomised, Uncontrolled Trial Investigating the Pharmacokinetics of CRD007 After Single Dose Administration to Subjects With Abdominal Aortic Aneurysm (AAA)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Abdominal Aortic Aneurisms
Lead sponsor: RSPR Pharma AB
Sponsor class: INDUSTRY
First posted: 2012-11-08
Enrollment: 18
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of the study is to determine the plasma levels of CRD007 in patients with abdominal aortic aneurysms after the administration of single doses of tablets containing 10, 25 and 40 mg CRD007.


Eligibility criteria: Inclusion Criteria:

* Infra-renal abdominal aortic aneurysm

Exclusion Criteria:

* Significant concurrent disease or medical conditions that are deemed to interfere with the pharmacokinetics or the safety of CRD007 conduct of the trial

Primary outcomes:
measure: Pharmacokinetics - maximum plasma concentration (Cmax)
timeFrame: Pre-dose and until 12 hours post-dose
measure: Pharmacokinetics - time to maximum plasma concentration (tmax)
timeFrame: Pre-dose til 12 hours post-dose
measure: Pharmacokinetics - Area under the plasma concentration curve (AUC)
timeFrame: Pre-dose until 12 hours post-dose
measure: Pharmacokinetics - elimination half life (t1/2)
timeFrame: pre-dose until 12 hours post-dose
Secondary outcomes:
measure: Dose linearity
timeFrame: Pre-dose and until 12 hours post-dose
measure: Potential for accumulation
timeFrame: Pre-dose untill 12 hours post-dose
Other outcomes:
Locations:
city: Viborg
country: Denmark
facility: Department of Vascular Surgery Viborg Hospital
Study officials:
affiliation: Department of Vascular Surgery Viborg Hospital Heiberg Allé 4 DK-8800 Viborg Denmark
name: Nikolaj F Groendal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04577118: The iotaSOFT Insertion System Safety Study
Official title: The iotaSOFT Insertion System Safety Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cochlear Implant
Lead sponsor: iotaMotion, Inc.
Sponsor class: INDUSTRY
First posted: 2020-10-06
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Non-significant risk evaluation of the iotaSOFT Insertion System when used by a surgeon to assist with inserting a cochlear implant electrode array.

Detailed description: This is a confirmatory study to assess successful peri-procedural use of the iotaSOFT Insertion System and potential adverse events that may be caused by use of the system during cochlear implant surgery.

Eligibility criteria: Key Inclusion Criteria:

* Candidate for cochlear implantation per indications
* Age 18 years or older

Key Exclusion Criteria:

* Prior cochlear implantation in ear to be treated
* Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode ray
* Craniofacial abnormality or abnormal cochlear/nerve anatomy on pre-operative CT or MR imaging
* Deafness due to lesions of the acoustic nerve or central auditory pathway
* Diagnosis of auditory neuropathy
* Active middle ear infection

Primary outcomes:
measure: Number of Subjects Experiencing a Peri-procedural Adverse Event Due to Use of the iotaSOFT Insertion System During Cochlear Implant Surgery
timeFrame: Day 0
Secondary outcomes:
measure: Successful Surgical Use of the iotaSOFT Insertion System During Cochlear Implant Surgery as Measured by a Surgeon Utility Questionnaire. The Questionnaire Will be Used to Calculate the Proportion of Subjects in Which the Device Performed as Intended.
timeFrame: Day 0
Other outcomes:
measure: Procedural Duration of Time for Insertion of the Electrode Array (Mean, Range)
timeFrame: Day 0
measure: Proportion of Subjects in Which the Cochlear Implant Electrode Was in the Correct Position Post-procedure
timeFrame: Day 0
measure: Adverse Events Reported During the Follow-up Period as Documented by Impedance and Neural Response Telemetry Testing. Adverse Events Will be Categorized by Type and Number of Participants Experiencing an Event.
timeFrame: 1 month
Locations:
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
Study officials:
affiliation: University of Iowa
name: Bruce Gantz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04682418: Pedicle Screw Placement With XVS
Official title: Feasibility Study of Pedicle Screw Placement in the Spine With the XVISION SPINE System
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spine Fusion
Lead sponsor: Augmedics
Sponsor class: INDUSTRY
First posted: 2020-12-23
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Open label, prospective, single arm, multi-center study. Pedicle screws placement in sacral/lumbar vertebrae will be performed via open procedural technique, by at least two (2) different surgeons, using the XVISION SPINE system.

Pedicle screw placement accuracy will be assessed by two independent, experienced radiologists, using the Gertzbein score.

Subjects will undergo intraoperative 3D scan prior to screws placement to enable 3D model rendering and XVISION SPINE system registration.

Subjects will undergo intraoperative 3D scan post procedure to enable offline scoring of pedicle screw placement using the Gertzbein score.

Surgeons performing the procedures will be requested to fill in usability questionnaires at the end of the procedure


Eligibility criteria: Inclusion Criteria:

1. Subjects aged 18 - 80 yrs.
2. Subjects with Spondylosis scheduled to undergo an elective short (6 or less consecutive vertebrae) S1-L1 open spinal fixation surgery using pedicle screws.
3. Subjects requiring a posterior approach surgical procedure.
4. Subjects with normal global spinal alignment (coronal, sagittal view) and/ or patients with degenerative spine disorders.

Exclusion Criteria:

1. Subjects with severe Osteoporosis (T score \<-3.5)
2. Subjects with kyphosis at the operated area (≥ stage 3)
3. Subjects with Spondylolisthesis Grade III and above.
4. Subjects scheduled for revision fusion surgery (prior laminectomy or discectomy is not excluded).
5. Subjects with significant abnormalities of bones (e.g. osteogenesis imperfecta, tumors, infection or malignancy, etc.)
6. Subjects with neurologic diseases or damage (e.g. due to trauma, tumor, Charcot-Marie Tooth, Guillain-Barre syndrome, cerebral palsy, spina bifida or neurofibroma)
7. Subjects with spinal cord abnormalities with any neurologic symptoms or signs
8. Paraplegia.
9. Pedicle fracture documented before or during surgery.
10. Women pregnant or lactating
11. Subjects requiring anterior release or instrumentation.
12. Subjects who are unwilling to sign written informed consent and assent to participate in the study.

    -

Primary outcomes:
measure: accurate placement of pedicle screws
timeFrame: through study completion , an average of 6 months.
Secondary outcomes:
measure: usability and ease of use of the system: questionnaire
timeFrame: The surgeon fills a questionnaire after the surgery, within 7 days.
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Haemek MC
city: Tel HaShomer
country: Israel
facility: Sheeba Medical Center
city: Tzrifin
country: Israel
facility: Asaf Harofeh
Study officials:
References: